News

November 7, 2019 “Commencement of Clinical Trial of Boron Neutron Capture Therapy (BNCT) for Malignant Melanoma and Angiosarcoma” issued.
Oct 15, 2019 STELLA PHARMA CORPORATION has recently filed for approval to manufacture and sell a boron agent for BNCT.
May 8, 2019 STELLA PHARMA CORPORATION has initiated consulting with PMDA for ‘SAKIGAKE Designation System’on SPM-011 after realizing achievement of their established goal on the clinical trial of Head & Neck cancer.
April 21, 2017 SPM-011 has been approved for prioritized review under the SAKIGAKE Designation System.
February 28, 2017 A leading-edge project we are collaboratively developing with Sumitomo Heavy Industries, the “Boron Neutron Capture Therapy (BNCT) System” has been approved for prioritized review under the SAKIGAKE Designation System.